Latest Content

In this Q&A, LENZ CFO Dan Chevallard on Vizz's ECP momentum, telehealth expansion, and the global push to end reading glasses for presbyopia.

Antineoplastics were the most frequently implicated drug class in review

The company said it will now focus solely on developing what it describes as the first small-molecule sustained-release implant for geographic atrophy, with clinical trials expected to begin in 2028.

Neda Gioia, OD, CNS, FMCP, FOWNS, CFMP, stated that preparing optometric students for the possibility of burnout may help reduce its prevalence.

Mila Ioussifova, OD, CNS, FAAO, FOWNS, details her AOA Optometry's Meeting 2026 session.

Alcon's TikTok, YouTube, and Instagram campaign uses creator-led patient stories to reintroduce LASIK to younger consumers and prompt conversations with surgeons.

Erin Rueff, OD, PhD, FAAO, provides tips to fellow clinicians on how to keep these patients comfortable in their lenses.

Healome’s proprietary eye drop-matrix behaves like a liquid when it is dropped on the eye, and then restructures on the ocular surface to form a clear, lubricating, protective matrix that can deliver a broad range of drugs.

Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop, for the treatment of presbyopia in adults.

Screen time's derailing of the circadian rhythm could contribute to behavioral difficulties in pediatric patients.

The new patient, secured by Provectus and VisiRose, supports a light-independent rose bengal eye drop that fights MRSA and other drug-resistant keratitis, erases biofilms, and enables self-administered treatment.

The FDA issued a nationwide recall of a steroid eye drop.

The approval is backed by Phase 3 bridging data—expanding EyeSol options and intensifying market rollout.